The Microbiota in Kidney Donation and Transplantation

NCT ID: NCT04388930

Last Updated: 2023-12-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

130 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-03-01

Study Completion Date

2025-06-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The human gastrointestinal tract harbours \~40 trillion microbial cells, far outnumbering the cell number, and therefore the genetic content of its host. How this genetically diverse bacterial (collectively referred as 'microbiota') co-resident modulates host homeostasis is largely unknown. We are increasing gaining a better understanding how the microbes modulate mucosal and systemic metabolic/immune and organ systems including the kidney, heart and the brain. Therapeutic targeting of the gastrointestinal (GI) microbiota may help improve clinical outcomes in conditions as diverse as arthritis, cardiovascular disease, and cancer. In contrast to other organ systems, studies investigating the role of the microbiota in modulating clinical outcomes in renal transplantation lags behind.

The aim of the study is to examine (a) how alterations in the urinary and GI microbiota and associated metabolites impact on host immunity after renal transplantation, and (b) whether such changes are correlated with post-transplant complications, such as rejection, development of de novo donor specific antibodies, metabolic complications (e.g post-transplant diabetes) and infections. Participants will be followed before and up to twelve months post-transplantation, and, longitudinal microbial data will be correlated with in-depth immune phenotyping and clinical end-points to define the impact that changes in urinary and GI microbial ecology have on kidney transplant outcomes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Diseases Kidney Transplant Failure and Rejection Urinary Tract Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Kidney transplant live-donor

Participants that will be a planned live renal transplant donor

Pre-operative assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing

Post-operative day 3 assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Post-operative week 4-6 assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Post-operative 3 month assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Pre-operative 6 month assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Post-operative month 12 recipient assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Kidney transplant recipient

Renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible live-donor or cadaveric transplant

Pre-operative assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing

Post-operative week 4-6 assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Post-operative 3 month assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Pre-operative 6 month assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Post-operative month 12 recipient assessment - blood, urine, & faecal sample

Intervention Type OTHER

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pre-operative assessment - blood, urine, & faecal sample

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing

Intervention Type OTHER

Post-operative day 3 assessment - blood, urine, & faecal sample

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Intervention Type OTHER

Post-operative week 4-6 assessment - blood, urine, & faecal sample

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Intervention Type OTHER

Post-operative 3 month assessment - blood, urine, & faecal sample

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Intervention Type OTHER

Pre-operative 6 month assessment - blood, urine, & faecal sample

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Intervention Type OTHER

Post-operative month 12 recipient assessment - blood, urine, & faecal sample

Blood sample for multi-parametric flow cytometry. Blood and urine samples for identifying microbial-associated metabolite signature.

Urine and faecal samples for 16S rRNA gene sequencing.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All adult (≥18 years old) undergoing living donor nephrectomy or kidney transplantation. Patients willing to provide samples including Urine, Blood, Faecal samples.

1. Participant able to give Informed Consent
2. All patients will be at least 18 years old
3. Patients will either be a live renal transplant donor or a renal transplant recipient on the waiting list to have or will have had an ABO-blood group compatible renal transplant.
4. Patients attending hospital clinics at participating centre for routine clinical follow -up.
5. Patients willing to comply with study procedures and willing to provide blood, faecal and urine samples.

Exclusion Criteria

1. Patients under the age of 18 years
2. Patients unable to give informed consent
3. Patients not able to comply with study procedures or follow-up visits
4. Patients that are not a live renal donor or that are not on the waiting list to have or have not had an ABO blood group compatible renal transplant and are not attending hospital outpatient clinics at participating study centres for routine clinical follow-up.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University College, London

OTHER

Sponsor Role collaborator

Royal Free Hospital NHS Foundation Trust

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Research and Development Manager

Role: STUDY_CHAIR

Sponsor GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Royal Free London NHS Trust

London, , United Kingdom

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Reza Motallebzadeh

Role: CONTACT

Phone: 020 7794 0500

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Reza Motallebzadeh, PhD FRCS

Role: primary

Amanda Bidle

Role: backup

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Informed Consent Form

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

125570

Identifier Type: -

Identifier Source: org_study_id